Skin boosters are used to improve skin quality rather than create the structural volume associated with dermal fillers. For UK aesthetic practitioners, the important question is not simply which product is most popular, but which category best matches the treatment objective, the product’s intended purpose, the available evidence and the practitioner’s training.
This practitioner guide compares skin boosters, HA bio-remodelling products, polynucleotides and structural dermal fillers, and provides a practical framework for evaluating products before adding them to a clinic range.
What Are Skin Boosters?
“Skin booster” is a broad commercial term rather than a single formulation. Products grouped under it may include non-cross-linked or lightly stabilised hyaluronic acid formulations, high-concentration HA bio-remodelling products and other injectable products intended to support skin-quality outcomes. Polynucleotides are also frequently discussed alongside skin boosters, although they are chemically and mechanistically distinct from HA products.
The common treatment objective is improvement in skin quality — such as hydration, texture, elasticity or the appearance of fine lines — rather than projection or structural volumisation. Product-specific indications, intended purpose, instructions for use and evidence should always take precedence over assumptions based on the category name.
Skin Boosters vs Dermal Fillers: What Is the Difference?
The clearest distinction is skin quality versus structural correction.
Most structural dermal fillers use cross-linked hyaluronic acid gels engineered to provide varying degrees of projection, support, contour or volume. Their physical behaviour depends on properties including elasticity, cohesivity and viscosity, which influence how a product performs in tissue.
Skin boosters generally pursue a different endpoint. Rather than being selected primarily to reshape or replace volume, they are used when the treatment objective centres on the quality and appearance of the skin itself.
This means skin boosters and dermal fillers should not be treated as interchangeable products. In appropriate patients they may be complementary: a structural filler may address volume or contour while a skin-quality treatment addresses different concerns in the overlying skin.
Practitioners comparing these categories can also read our Profhilo vs Dermal Fillers practitioner guide and explore the Skin Boosters collection.
Hyaluronic Acid Skin Boosters
Hyaluronic acid is naturally present in the extracellular matrix and has a strong affinity for water. In aesthetic products, however, HA formulations vary substantially. Concentration alone does not tell a practitioner how a product will behave: molecular weight, cross-linking or stabilisation, rheology, formulation and intended tissue interaction all matter.
That is why practitioners should avoid treating all HA injectables as equivalent. A product designed for superficial skin-quality treatment should not be evaluated by the same criteria as a structural filler designed for projection or deep support.
For more detail on the underlying science, see Hyaluronic Acid Molecular Weight: What the Evidence Shows.
HA Bio-Remodelling and Profhilo
Bio-remodelling products sit within the wider skin-quality conversation but have their own formulation characteristics and manufacturer-defined intended purposes. Profhilo is one of the best-known examples in the UK aesthetics market and uses a thermally stabilised hybrid cooperative complex of high- and low-molecular-weight hyaluronic acid.
Published clinical literature reports improvements in selected skin-quality parameters with injectable HA formulations, but practitioners should distinguish evidence for a specific formulation from evidence for hyaluronic acid as a broad category. Claims made for one product cannot automatically be transferred to another.
Practitioners considering this category can explore Profhilo products and review our Profhilo vs Dermal Fillers guide.
Where Do Polynucleotides Fit?
Polynucleotides are not hyaluronic acid dermal fillers. They are nucleotide-based products increasingly used in regenerative and skin-quality-focused aesthetic practice. They are often grouped commercially with skin boosters because of overlapping treatment goals, but the underlying materials and proposed biological mechanisms differ.
The clinical evidence for PN/PDRN is developing. Recent reviews describe promising skin-quality and regenerative applications while also highlighting heterogeneity between formulations, protocols and studies. Practitioners should therefore avoid assuming that evidence for one PN or PDRN formulation establishes identical outcomes for every product in the category.
For a deeper review, read Polynucleotides: A UK Practitioner Guide.
Skin Boosters vs Polynucleotides
The choice should begin with the treatment objective and the individual product rather than a blanket judgement that one category is “better”. HA-based skin boosters are principally associated with hydration and skin-quality support, while PN/PDRN products are positioned around tissue-quality and regenerative pathways. The evidence base, formulation and intended purpose vary within both categories.
For clinic procurement, practitioners should compare product-specific evidence, manufacturer documentation, intended purpose, training requirements, treatment protocol, repeat-treatment pattern and realistic patient demand.
How Should Practitioners Choose a Skin Booster?
A useful product-selection framework considers five areas:
- Treatment objective: hydration, texture, elasticity, fine lines, regenerative skin-quality support or structural correction are not the same objective.
- Product-specific evidence: look for clinical evidence relevant to the actual formulation rather than relying on claims about an ingredient or category generally.
- Training and competence: practitioners should be appropriately trained for the product and procedure they provide.
- Intended purpose and IFU: check the manufacturer’s current instructions, contraindications, storage requirements and intended use.
- Clinic demand and stock turnover: a focused range that turns predictably is usually more commercially sensible than holding numerous overlapping products.
UK Regulatory and Product-Sourcing Considerations
Practitioners should verify the regulatory status of each individual product rather than assuming every injectable marketed as a skin booster or polynucleotide has the same classification. In Great Britain, medical devices are regulated under the UK Medical Devices Regulations 2002 (as amended), and applicable conformity marking and market-access requirements depend on the device and route to market. CE-marked medical devices continue to be recognised in Great Britain under transitional arrangements, with deadlines depending on the applicable legislation.
Where a product is a medical device, practitioners should use it in accordance with the manufacturer’s intended purpose and current instructions for use. Product provenance, batch and expiry traceability, storage requirements and relevant documentation should form part of procurement decisions.
Storage, Handling and Stock Control
Do not assume all skin boosters, fillers and polynucleotides share the same storage requirements. Follow the current manufacturer IFU and product labelling for each formulation. Maintain batch and expiry traceability and rotate stock appropriately.
Our Dermal Filler Storage and Handling: A UK Clinic Guide provides a broader framework for clinic stock governance.
Building a Focused Clinic Range
A strong clinic range does not need to contain every trending injectable. A more defensible approach is to select products that cover clearly different treatment objectives, understand those products thoroughly and reorder according to genuine demand.
Before adding a product, ask: What treatment objective does this fill in our current range? What evidence supports this specific formulation? Are practitioners appropriately trained? What documentation and traceability are available? How frequently will it realistically be used? Does it duplicate something already on the shelf?
Explore Skin-Quality Products at Longeva Aesthetics
Longeva Aesthetics supplies professional aesthetic products to practitioners and clinics. Explore the relevant ranges:
Choose products by treatment objective, evidence and clinical suitability — then build a range your clinic understands and can use consistently.
Frequently Asked Questions
What is the difference between skin boosters and dermal fillers?
Dermal fillers are generally selected for structural volume, contour, projection or support. Skin boosters are generally selected when the primary objective is skin quality, such as hydration, texture or elasticity. Product formulations and intended purposes vary, so practitioners should always check the individual product documentation.
Do skin boosters add volume?
Skin boosters are not generally selected to create the structural volumisation associated with conventional dermal fillers. Some injectable products may produce temporary tissue effects, but their intended treatment objective should be determined from the specific product and manufacturer information.
Are polynucleotides skin boosters?
Polynucleotides are chemically distinct from hyaluronic acid skin boosters. They are frequently grouped within the broader skin-quality category because practitioners may use them for overlapping aesthetic objectives, but their composition, proposed mechanisms and evidence base differ.
Is Profhilo a dermal filler?
Profhilo is an injectable hyaluronic acid product used for bio-remodelling and skin-quality indications rather than conventional structural volumisation. Practitioners should follow the manufacturer’s current intended purpose and instructions for use.
What should practitioners check before buying a skin booster?
Check the product’s intended purpose, manufacturer documentation, regulatory status where applicable, evidence, practitioner training requirements, storage instructions, batch and expiry traceability, treatment protocol and realistic clinic demand.